Published on 27 Mar 2024 on Zacks via Yahoo Finance
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics, Inc. STOK reported encouraging new data from two phase I/IIa studies and two open-label extension (OLE) studies evaluating investigational candidate,STK-001, in children and adolescents aged two to 18 years with Dravet syndrome.
STK-001 is Stoke Therapeutics’ novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome, rather than just treating the symptoms like currently available treatments.
Per the data readout from the studies, treatment with STK-001 demonstrated clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification.